Skip to main content
Caplight Logo









Palleon Pharmaceuticals

Palleon Pharmaceuticals

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://palleonpharma.com/

Last Round

Series B

Sep 17, 2020

Est. Valuation

$238.83M

Total Funding Raised

$147.6M

Company Overview

Palleon Pharmaceuticals is a biotechnology company that develops glyco-immunology therapeutics to treat cancer and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

glyco-immunologycancer immunotherapyglycobiologysialic acidbiotech drug discoverytumor microenvironmentglycan-based therapeuticsimmuno-oncologyenzymatic platformsclinical-stage biotechtranslational assaysdrug licensingprecision medicinebiopharma partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Palleon Pharmaceuticals Comparables

Compare Palleon Pharmaceuticals with similar companies based on industry and business-model similarity.

Palleon Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OncoC4, Inc.
81%
Valora Therapeutics Inc.
79%
Tacalyx
77%

Palleon Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 17, 2020
Series AOct 4, 2017

Key People

Founding team and executive leadership

Jim Broderick

CEO And Founder

Founding Team

Stefani Wolff

Chief Operating Officer

Executive Team

Palleon Pharmaceuticals Investors

Notable investors and investment history

Palleon Pharmaceuticals investors
InvestorRounds
Surveyor CapitalSeries B
Vertex Ventures HCSeries A, Series B
AbbVie VenturesSeries A, Series B
CitadelSeries B
Matrix Capital ManagementSeries B
Pfizer VenturesSeries B, Series A
Takeda VenturesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Presented B7-H3 Targeted Sialidase at the 2026 AACR Annual Meeting.

  • Apr 2, 2026

    Presenting product candidate HLX316/E-688 at AACR Annual Meeting.

Palleon Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Palleon Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Palleon Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range22
Year Founded2015
Last FundingSep 17, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?